Topical Agents for the Management of Oral Complications in Cancer Patients
Judith E Raber-Durlacher, Joel B Epstein
Severe OM may result in dose reduction, dose delay, and even in termination of planned therapy.In addition, OM is associated with considerable cost implications, ranging from US$12,000 in patients with solid tumors 7,8 to US$42,000 in HCT patients.9 In radiation-induced OM, initial mucosal whitening may occur prior to erythema and mucosal ulceration. Mucosal lesions that […]